Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Steven Shiff, M.D.
Intercept Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
- Hospital Universitario Austral
Buenos Aires, Argentina
- Hospital Aleman
Caba, Argentina
- Hospital Britanico de Buenos Aires
Caba, Argentina
- Hospital de Gastroenterologia "dr Carlos Bonorino Udaondo"
Ciudad Autonoma de Buenos Aire, Argentina
- Higea S.A.
Mendoza, Argentina
- Hospital Universitario Austral
Pilar, Argentina
- Hospital Provincial del Centenario
Rosario, Argentina
- Royal Prince Alfred Hospital
Camperdown, Australia
- Nepean Hospital
Kingswood, Australia
- Cub Hospital Erasme
Brussels, Belgium
- Universitair Ziekenhuis Antwerpen Uza
Edegem, Belgium
- University Hospital Leuven
Leuven, Belgium
- Hospital Das Clínicas Da Universidade Federal de Minas Gerais - Ufmg
Belo Horizonte, Brazil
- Hospital de Clinicas de Porto Alegre
Rio Grande, Brazil
- Hospital Das Clinicas Da Faculdade de Medicina Da Universidade de São Paulo
São Paulo, Brazil
- Toronto General Hospital
Toronto, Canada
- West Tallinn Central Hospital
Tallinn, Estonia
- Tartu University Hospital
Tartu, Estonia
- Universitatsklinikum Leipzig Aor
Leipzig, Germany
- Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat-Gasztroenterologia-Hepatologia
Békéscsaba, Hungary
- Azienda Socio Sanitaria Territoriale (asst) Di Monza
Monza, MB, Italy
- Aou Ospedale Civile S. Agostino Estense - Uo Medicina Metabolica
Modena, Italy
- Hospital of Lithuanian University of Health Sciences Kauno Klinikos
Kaunas, Lithuania
- Klaipeda Seamen'S Hospital
Klaipėda, Lithuania
- Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
- Paseo Vall D'Hebron
Barcelona, Spain
- Hospital Universitario Virgen del Rocio
Seville, Spain
- Hospital Universitari I Politecnic la Fe de Valencia
Valencia, Spain
- Inland Empire Liver Foundation
Rialto, California, United States
- University of California, Ddavis Medical Center
Sacramento, California, United States
- Schiff Center for Liver Diseases/ University of Miami
Miami, Florida, United States
- Mercy Medical Center
Baltimore, Maryland, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Kansas City Research Institute
Kansas City, Missouri, United States
- the Ohio State University Wexner Medical Center
Columbus, Ohio, United States
- Upmc Center for Liver Diseases
Pittsburgh, Pennsylvania, United States
- the Liver Institute at Methodist Dallas Medical Center
Dallas, Texas, United States
- Baylor College of Medicine- Advanced Liver Therapies
Houston, Texas, United States
- American Research Corporation at Thetexas Liver Institute
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Jun 2018
- Primary completion
- 9 Jul 2021
- Completion
- 9 Jul 2021
- Last update posted
- 6 Sept 2022
- Registered enrollment
- 22
- Registry id
- NCT03633227
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.